Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.VGX Pharmaceuticals has reported the successful completion of its first study to assess the tolerability of the company's patented Cellectra electroporation device in humans.
Subscribe to our email newsletter
Ten healthy adult volunteers were treated with Cellectra device and were asked to report the level of discomfort they experienced immediately after electroporation and at various times thereafter. The procedure was generally well tolerated.
Joseph Kim, president and CEO of VGX Pharmaceuticals, said: “This is just the first step in our aggressive strategy to develop a potent and prolific DNA-based drug and vaccine development platform.”